Trials / Completed
CompletedNCT01893268
An Observational Study of Avastin (Bevacizumab) in Elderly Patients With Non-Squamous Non-Small Cell Lung Cancer in Clinical Practice
Therapeutic Strategies Including Avastin as 1st Line Therapy in Elderly Patients Suffering From Advanced (IIIB/IV Stage) Non-squamous Non-small Cell Lung Cancer, in Routine Clinical Practice.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 279 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Not accepted
Summary
This prospective, observational study will assess the effectiveness and safety of Avastin (bevacizumab) as 1st line therapy in elderly patients with advanced non-squamous non-small cell lung cancer in clinical practice. Therapy with Avastin and standard chemotherapy will be administered according to the treating physician. Data will be collected for approximately 4 years.
Conditions
Timeline
- Start date
- 2013-07-25
- Primary completion
- 2018-03-20
- Completion
- 2018-03-20
- First posted
- 2013-07-08
- Last updated
- 2018-05-14
Locations
88 sites across 1 country: France
Source: ClinicalTrials.gov record NCT01893268. Inclusion in this directory is not an endorsement.